Lung cancer.

@article{Herbst2008LungC,
  title={Lung cancer.},
  author={Roy S. Herbst and John V. Heymach and Scott M. Lippman},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 13},
  pages={
          1367-80
        }
}
From the Departments of Thoracic/Head and Neck Medical Oncology (R.S.H., J.V.H., S.M.L.), Cancer Biology (R.S.H., J.V.H.), and Clinical Cancer Prevention (S.M.L.), University of Texas M.D. Anderson Cancer Center, Houston. Address reprint requests to Dr. Lippman at the Department of Thoracic/Head and Neck Medical Oncology, Unit 432, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, or at slippman@ mdanderson.org. 

Figures and Tables from this paper

Systemic Therapy for Lung Cancer for the Radiation Oncologist

TLDR
HDRs are a new class of agents that will require extensive evaluation in lung cancer as they lead to the inhibition of transcription of key cell cycle regulatory genes and are linked to the pathogenesis and progression of cancer.

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

TLDR
An updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain is provided to assist oncologists to improve current clinical practice towards a better prognosis for these patients.

L LC Non-Small Cell Lung Cancer : Screening , Diagnosis , and Staging

TLDR
The tumor node metastasis (TNM) International Staging System provides useful prognostic information and is used to stage all patients with non-small cell lung cancer, and recent trials added new data on screening and diagnostic approach.

Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.

TLDR
The molecular diagnostics available and under development for established and emerging targets, and how these may be integrated into current treatment algorithms are discussed, and their interactions with the medical oncologist, and/or thoracic surgeon and radiation oncologists are discussed.

Analysis of Factors Affecting Brain Metastasis in Limited-Stage Small-Cell Lung Cancer Treated With Definitive Thoracic Irradiation

TLDR
Poor short-term response to TRT and huger Dmax-T were risk factors for BM, and AC following TRT improved patient survival, but not decreased BM, but further prospective clinical trials are required to confirm these conclusions.

Non-Small Cell Lung Cancer With Synchronous Peritoneal Adenocarcinoma: A Rare Independent Combination

TLDR
Physicians should be familiar with an independent presentation of squamous cell carcinoma of the lung and peritoneal carcinomatosis in the same patient, as the outcome of independent tumors is poor in most cases.

Does Cell Type in Lung Cancer Have any Clinical Importance?

  • C. Yuksel
  • Medicine
    European Journal of Therapeutics
  • 2018
TLDR
Lung cancer is the leading cause of deaths from cancer in men, and it has reached 16.5% and started to surpass deaths due to breast cancer in women and is estimated to constitute nearly 80-85% of all lung cancers today.

Non-Small Cell Lung Cancer: Screening, Diagnosis, and Staging

TLDR
The tumor node metastasis (TNM) International Staging System provides useful prognostic information and is used to stage all patients with non-small cell lung cancer, and recent trials added new data on screening and diagnostic approach.

Diagnosis and Molecular Classification of Lung Cancer.

TLDR
This chapter will review the main current basis of the pathological diagnosis and classification of lung cancer incorporating the histopathological and molecular dimensions of the disease.

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

TLDR
Cumulative data from several retrospective and small prospective studies suggest that molecularly targeted systemic therapies may be an effective option for the treatment of BM from NSCLC, breast cancer, and melanoma, either as monotherapy or in conjunction with other therapies.
...

References

SHOWING 1-10 OF 155 REFERENCES

Molecular signatures of lung cancer--toward personalized therapy.

TLDR
A major effort to improve the control of lung cancer entails the use of molecular profiling to characterize tumors and provide accurate predictions of the outcome after standard or novel treatments.

Molecular changes in the bronchial epithelium of patients with small cell lung cancer.

  • I. WistubaJ. Berry A. Gazdar
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
It is indicated that extensive genetic damage in the accompanying normal and hyperplastic bronchial epithelium is characteristic of SCLC tumors and suggest major differences in the pathogenesis of the three major lung cancer types.

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

TLDR
The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

TLDR
Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.

Lung cancer in never smokers — a different disease

TLDR
Current knowledge of lung cancers arising in never smokers versus smokers is summarized, suggesting that they are separate entities.

A Prediction Model for Lung Cancer Diagnosis that Integrates Genomic and Clinical Features

TLDR
The findings suggest that use of the clinicogenomic model may expedite more invasive testing and definitive therapy for smokers with lung cancer and reduce invasive diagnostic procedures for individuals without lung cancer.

DNA methylation markers and early recurrence in stage I lung cancer.

TLDR
Methylation of the promoter region of the four genes in patients with stage I NSCLC treated with curative intent by means of surgery is associated with early recurrence.

Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer

TLDR
Findings indicate that gene expression in cytologically normal large-airway epithelial cells can serve as a lung cancer biomarker, potentially owing to a cancer-specific airway-wide response to cigarette smoke.

Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer.

TLDR
It is indicated that multiple small clonal or subclonal patches containing molecular abnormalities are present in normal or slightly abnormal bronchial epithelium of patients with lung cancer.

Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy.

  • M. MeyersonD. Carbone
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Analyses of the relationship between expression profiles and tumor development and differentiation, the presence or absence of specific pathogenic mutations, patient prognosis and survival after surgical treatment, and specific histopathology all appear to be promising.
...